Nektar Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio1.741.204.6124.4719.94
P/B Ratio2.820.821.163.672.83
Price/Tangible Book2.820.821.464.133.05
Enterprise Value Ratios
EV/Revenue1.311.9418.3113.84
Profitability & Returns
Return on Equity (ROE)-1.24%-1.11%-0.70%-0.60%-0.36%
Return on Assets (ROA)-0.23%-0.15%-0.16%-0.21%-0.14%
Return on Invested Capital (ROIC)-4.51%-1.31%-1.11%-1.37%-0.82%
Return on Capital Employed (ROCE)-0.54%-0.39%-0.37%-0.43%-0.27%
Leverage & Solvency Ratios
Debt/Equity3.201.760.780.500.33
Liquidity Ratios
Current Ratio4.266.458.019.349.83
Quick Ratio4.185.977.538.899.55
Efficiency Ratios
Asset Turnover0.280.160.100.080.09
Inventory Turnover1.911.241.601.39
Yield & Distribution Ratios
Earnings Yield-0.69%-2.56%-0.87%-0.21%-0.15%
FCF Yield-1.03%-1.79%-0.73%-0.17%-0.11%
Buyback Yield-0.08%-0.02%-0.02%-0.03%-0.02%